BioAtla, Inc. (NASDAQ:BCAB) Insider Acquires $43,022.08 in Stock

BioAtla, Inc. (NASDAQ:BCABGet Rating) insider Christian Vasquez acquired 14,152 shares of the stock in a transaction dated Tuesday, June 7th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $43,022.08. Following the completion of the transaction, the insider now owns 38,677 shares of the company’s stock, valued at approximately $117,578.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Christian Vasquez also recently made the following trade(s):

  • On Thursday, June 9th, Christian Vasquez purchased 10,000 shares of BioAtla stock. The stock was bought at an average cost of $2.97 per share, for a total transaction of $29,700.00.

BioAtla stock traded down $0.01 on Thursday, reaching $3.03. The company’s stock had a trading volume of 225,055 shares, compared to its average volume of 669,656. The company has a market cap of $113.36 million, a price-to-earnings ratio of -1.06 and a beta of 2.49. The business’s fifty day moving average price is $3.31 and its 200 day moving average price is $9.45. BioAtla, Inc. has a twelve month low of $2.01 and a twelve month high of $51.83.

BioAtla (NASDAQ:BCABGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.04. As a group, equities research analysts forecast that BioAtla, Inc. will post -2.72 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of BCAB. Great Point Partners LLC acquired a new position in shares of BioAtla during the third quarter valued at $24,847,000. Janus Henderson Group PLC lifted its stake in shares of BioAtla by 72.5% during the third quarter. Janus Henderson Group PLC now owns 1,729,734 shares of the company’s stock valued at $50,918,000 after acquiring an additional 727,103 shares during the period. Renaissance Technologies LLC lifted its stake in shares of BioAtla by 656.7% during the first quarter. Renaissance Technologies LLC now owns 536,469 shares of the company’s stock valued at $2,682,000 after acquiring an additional 465,569 shares during the period. BlackRock Inc. lifted its stake in shares of BioAtla by 24.8% during the fourth quarter. BlackRock Inc. now owns 1,585,894 shares of the company’s stock valued at $31,130,000 after acquiring an additional 315,203 shares during the period. Finally, Woodline Partners LP lifted its stake in shares of BioAtla by 196.1% during the fourth quarter. Woodline Partners LP now owns 446,141 shares of the company’s stock valued at $8,758,000 after acquiring an additional 295,446 shares during the period. 70.79% of the stock is currently owned by institutional investors.

Several analysts recently commented on BCAB shares. HC Wainwright started coverage on BioAtla in a research note on Monday, March 21st. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Investment Research lowered BioAtla from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Finally, Credit Suisse Group lowered BioAtla from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $5.00 in a research note on Thursday, May 5th.

BioAtla Company Profile (Get Rating)

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Featured Articles

Insider Buying and Selling by Quarter for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.